CLINICAL TRIALS

Asia-Pacific sees the largest growth in metabolic disorders-related trials over the past decade

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

An analysis of 10 years' worth of clinical trials data from GlobalData shows an increasing trend in metabolic disorders-related trials in the APAC region.

Powered by 

The Asia-Pacific region has seen a 11% increase in the number of metabolic disorders trials taking place over the past decade, the largest increase for any region worldwide.

The region now ranks in first for percentage growth in the number of trials taking place, compared to its fifth placed ranking in 2010.

These figures come from GlobalData's extensive clinical trials database which seeks to track the number of clinical trials taking place in countries around the world, in numerous therapy areas.

Asia-Pacific

The Asia-Pacific region saw the biggest increase in metabolic disorders related trials. Between 2010 and 2020, there was a 11% increase in the number of trials taking place.

In 2020, the largest proportion of trials in the region took place in China with 46.2% of all trials in the region taking place there. India and Japan had the next largest percentage of trials taking place in the region with 13.7% and 9.9%, respectively.

Middle East

The Middle East saw a 12% decrease in the number of metabolic disorders trials taking place. Iran saw the largest amount of trials taking place, in 2020, at 67.6%. Trials in Israel and Saudi Arabia also made up a large proportion of the trials taking place with 22.5% and 3.6%, respectively.

Europe

Europe saw a 37% decrease in the number trials taking place. Germany, the United Kingdom and Russia made up the most trials in the region, with 10.7%, 9.9% and 9.2%, respectively.

North America

North America saw a 38% decrease in metabolic disorders related trials taking place. The United States saw the largest percentage of trials taking place in the region at 79%. Canada and Mexico also made up a significant proportion of the trials taking place.

Africa

Africa saw a decrease in the number of metabolic disorders trials. The region saw a 45% decrease in the number of trials. Egypt made up 69% the largest proportion of trials taking place in the region. South Africa and Algeria also made up a large amount of the trials taking place with 6.9% and 6.9%, respectively.

South and Central America

South and Central America saw the biggest decrease in metabolic disorders trials. The number of trials in the region fell by 71% between 2010 and 2020. Brazil saw the largest percentage of trials taking place in the region with 36.1%.

Go to top

Go to top

02/24/2024 16:58:10
  • Home | Mapping the RNA therapeutics R&D landscape in 2022 
  • In this issue
  • Contents
  • CSafe Global
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • HOF Sonderanlagenbau
  • BEA Technologies
  • Comment
  • Restrictive Medicare coverage spells continued uncertainty for Aduhelm
  • 2021: a record year for orphan therapies
  • Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patients
  • Mimotopes Company Insight
  • Mimotopes
  • In Depth
  • Mapping the RNA therapeutics R&D landscape in 2022
  • A cloudy day in paradise for pharma tax havens in Cayman Islands & Bermuda?
  • Pharmaceutical Technology Excellence Awards 2021 – Winners Announced!
  • How technology could transform drug research in 2022
  • Anaesthesia drugs worst-hit by US drug shortages
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • In Data
  • Asia-Pacific sees the largest growth in metabolic disorders-related trials over
  • The Middle East has seen the largest growth in infectious disease-related trials over the past decade
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Baxter
  • Events
  • Next issue
01/20/2022 00:00:00